Optimal LDL-C Reductions in Patients with Atherosclerotic Cardiovascular Disease: Maximizing Clinical Benefit within the Department of Veterans Affairs

PROGRAM CHAIR & FACULTY PRESENTER

Christie M. Ballantyne, MD
Professor of Medicine
Chief of Cardiology & Cardiovascular Research
Director of the Clinic for Cardiometabolic Disease Prevention
Baylor College of Medicine
Houston, TX

TARGET AUDIENCE

This activity is intended for lipidologists, cardiologists, endocrinologists, and other healthcare professionals involved in the management of patients at high risk for CVD due to hypercholesterolemia.

LEARNING OBJECTIVES

After completing the CME activity, learners should be better able to:

  • Explain how lowering LDL-C levels reduces residual CVD risk in patients with persistent hypercholesterolemia and at high risk for poor CV outcomes
  • Review mechanisms of action, clinical profile, and the position of PCSK9 inhibitors in treatment regimens for patients with persistent hypercholesterolemia and at high risk for poor CV outcomes
  • Apply best practices for the identification and management of patients with persistent hypercholesterolemia and at high risk for poor CV outcomes who are candidates for tailored, intensified lipid-lowering regimens based on clinical guidance, individual patient risk factors, comorbidities, and prior treatment responses
  • Discuss the designs and results of long-term CV outcomes studies examining PCSK9 inhibitors in different patient populations with persistent hypercholesterolemia and at high risk for poor CV outcomes

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this web-based activity for a maximum of 0.75 AMA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the management of patients at high risk for CVD due to hypercholesterolemia
CNE Credits: 0.75 ANCC Contact Hours.

CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 0.75 contact hours of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Dr. Ballantyne reports for the past 12 months:
-Consultant for Abbott Diagnostic, Akcea, Amarin, Amgen, Arrowhead, Astra Zeneca, Boehringer Ingelheim, Corvidia, Denka Seiken, Esperion, Intercept, Janssen, Matinas BioPharma Inc, Merck, Novartis, Novo Nordisk, Regeneron, Roche Diagnostic, and Sanofi-Synthelabo
-Provisional patent for “Biomarkers to Improve Prediction of Heart Failure Risk” (patent no. 61721475) filed by Baylor College of Medicine and Roche

CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was peer-reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.

The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
Diana Tommasi, PharmD, Medical Director for Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP of Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
Jessica McMullen, MPH, Program Manager for Med Learning Group, has nothing to disclose.
Russie Allen of Accreditation and Outcomes for Med Learning Group has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During the course of this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:
1. Read the CME/CNE information and faculty disclosures
2. Participate in the enduring activity
3. Complete the online evaluation

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making ability before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/

RELEASE DATE: February 7, 2020

EXPIRATION DATE: February 7, 2021

Copyright © 2020 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

Scroll to Top

A Special Thank You to All HCPs

Med Learning Group sends its heartful gratitude to all healthcare professionals giving their all, 24/7, during this pandemic, despite the great risks they face. We cannot thank you enough for your courage and selfless service.

Connecting you with our personalized approach to continuing Medical Education

The Linking Approach to Education from Gap Analysis to Outcomes

Med Learning Group, a division of Ultimate Medical Academy, is a full-service accredited medical education company with commendation. Med Learning Group focuses on developing and implementing continuing education that improves healthcare practitioners’ ability to provide optimal care to their patients. Our goal is to provide high-quality education that is designed to deliver the highest level of outcomes for not only the practitioner, but also the patient. Med Learning Group has expertise in developing both live and online activities that are innovative, case-based, interactive and patient-centric in nature.

Med Learning Group has expertise in developing both live and online activities that are innovative, case-based, interactive and patient-centric in nature, and we focus on applying adult learning theory and principles to our programs. Even more importantly, we understand the nuances of our target audiences and design programs with a grounded understanding of how to educate both specialty audiences and general practitioners.